The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.
Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit https://www.TriConference.com/Precision-Medicine
Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field. For more information, please visit https://www.TriConference.com/Gene-Therapy
Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more For more information, please visit https://www.ImmunogenicitySummit.com/Workshop
Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health. For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics
Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead. For more information, please visit https://www.LiquidBiopsySummit.com/Programs
Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research. For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx
Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential. For more information, please visit https://www.TriConference.com/Digital-Pathology
Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently. For more information, please visit https://www.TriConference.com/Precision-Medicine
Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process. For more information, please visit https://www.triconference.com/Companion-Diagnostics
Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.
For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC is edging ever closer to front-line clinical care supporting advanced diagnostics, genetic counseling, and personalized medicine. While core bioinformatics applications aren’t going anywhere, modern medicine is increasingly a big data problem as well. Determining the optimal treatment depends on collaboration, the fusion of genetic data with other rich datasets like MRIs, ultrasound images, and population level studies. Increasingly analytics and AI techniques like machine learning are helping healthcare providers sift through massive amounts of data to make better decisions for patients more quickly and efficiently. For IT organizations, providing a foundation to support this rapid innovation has been challenging. With the need for increasingly specialized hardware, new application frameworks, cost challenges, and the need to share data as never before, institutions are increasingly embracing cloud computing. Univa has played a key role in helping life sciences companies manage diverse workloads on HPC clusters both on-premises and in the cloud. In this Podcast, Univa will discuss how workloads are evolving, share some of the pressures faced by their life-sciences customers, and discuss practical approaches to modernizing IT environments to support the increased variety of applications in the life sciences software ecosystem.
Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to the general public, gives us other personalized medicine examples and how it will affect the cost of medical care. For more information, please visit http://www.TriConference.com/Precision-Medicine
A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine
A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs
A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, Pfizer
Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field. For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/
Dr. Jeffrey Miller shares his experience in NK cell field in the last 20 years, comparing NK cells with T cells and their cost differences along with giving some advice to the young scientists in the field. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/
Dr. James Trager shares a preview of his talk at the NK cell-based cancer immunotherapy meeting in Boston, discusses his next step in research and the vision of Nkarta in NK cell therapy development and what he’s looking forward to at this meeting such as the topics of inhibition of MIC protein shedding and NK cell metabolism. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/
Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal. For more information, please visit http://www.PEGSummitEurope.com/Optimising-Protein-Expression Topics Questions Include: Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade? What potential solutions seem promising for some … challenges? Are there promising glimpses into using transient protein gene expression for clinical use today? You'll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?
Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress. For more information, please visit http://www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance
Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California Dr. Jennifer Dien Bard shares her insights into what the biggest challenges and opportunities are in implementing molecular point-of-care testing for infectious disease diagnostics, and rapid genetic and phenotypic susceptibility testing. Jennifer will be speaking at Molecular Diagnostics for Infectious Disease and co-instructing a short course on Rapid Diagnostics for Antimicrobial Resistance at the Next Generation Dx Summit August 20 to 24, 2018 in Washington, DC. For more information please visit http://www.NextGenerationDX.com/Infectious-Disease-Diagnostics/ and http://www.NextGenerationDX.com/SC-6/
Prof. Massimo Cristofanilli shares his perspective on the future of liquid biopsy, the complementary purposes of CTC and cfDNA technologies, and when one should expect clinical utility of liquid biopsies. For more information, please visit http://www.NextGenerationDx.com/Circulating-Tumor-Cells/
Dr. Bruce Quinn talks about his latest work, challenges to implementing precision medicine, advice for overcoming them and tips for integrating into the clinic. He discusses exciting new developments that are emerging and where the field is heading. For more information, please visit http://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics/
Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community and more. For more information, please visit http://www.NextGenerationDX.com/Reimbursement-Diagnostics/ and http://www.NextGenerationDX.com/Precision-Medicine/
Paul Yager of University of Washington speaks to CHI on May 4, 2018. Dr. Paul Yager from the University of Washington. Dr. Yager will be speaking at the Enabling Point-of-Care Diagnostics and the Microfluidics and Lab-on-a-Chip Devices for point-of-care testing tracks at the upcoming Next Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, DC. Topics include his lab’s success in developing NAAT testing, obstacles to developing low cost diagnostics and advice for those looking to get into the field. For more information, please visit http://www.NextGenerationDX.com/Point-of-Care-Diagnostics/ and http://www.NextGenerationDX.com/Microfluidics/
Suman Bose of Massachusetts Institute of Technology speaks to CHI on May 3, 2018. Dr. Bose will be speaking at the Single Cell Analysis and at the Microfluidics and Lab-on-a-Chip Devises for point of care testing tracks at the upcoming Next Generation Diagnostics Summit that is held from August 20th through the 24th in Washington, D.C. Topics include motivation for single cells analysis, overcoming challenges and outlooks for the Summit. For more information, please visit http://www.NextGenerationDX.com/Microfluidics/ and http://www.NextGenerationDX.com/Single-Cell-Analysis/
Dr. James Hendler of Rensselaer Polytechnic Institute speaks to Cambridge Healthtech Institute on April 13, 2018. He will be a presenter during the Machine Learning and Data Visualization & Exploration Tools tracks at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) What led you to work on precision wellness as a part of your research on artificial intelligence, agent-based computing, high-performance processing, and the Semantic Web (of which you’re one of the originators)? 2) Let’s discuss emerging technologies from machine learning and artificial intelligence. What applications do they have on healthcare? What’s their potential impact? 3) What role might AI-driven technologies have in enhancing data visualization in genomics, drug discovery, or clinical development? For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Visualization/ and http://www.Bio-ITWorldExpo.com/Machine-Learning-Genomics/
Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Let’s touch upon your gene discovery work. What determines the disease genes and conditions you study, with an eye on clinical impact? 2) How does research on rare and orphan disease enhance our understanding of medicine overall? 3) While you zoom in on rare diseases for the sake of broader knowledge, you also look broadly or globally to answer local questions, liaising between academia and industry, and partnering with clinicians with a shared goal of enhancing patient care. What do both the research and clinical sides need to contribute to the process, and what challenges still need to be ironed out? For more information, please visit http://www.bio-itworldexpo.com/clinical-omics/
Dr. Nirmala Shenoy of Rochester Institute of Technology speaks to Cambridge Healthtech Institute on April 6, 2018. She will be a presenter during the Data Transfer track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Why have you focused your recent research on Internet architectures and protocols and computational challenges faced by network protocols? 2) Let’s address scalability. How will supporting high-speed data transfers in large or across multiple networks, or provisioning for larger amounts of high-speed data, impact the security of scientific data? 3) How have Internet and routing protocols evolved in the last decade, and what further changes do you foresee in coming years? For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Transfer/
Tim Sweeney spoke to CHI to discuss his company’s work in using host response to diagnose and risk stratify patients with sepsis infections. He also discusses current shortcomings sepsis diagnostics, as well as what he sees as barriers in implementing rapid diagnostics and how the field is moving forward to overcome these barriers. For more information, please visit http://www.MolecularDXEurope.com/Infectious-Disease-Dx/
Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to unlock new mechanisms and pathways. Dr. Cho is speaking at the Blood-Brain Barrier conference, part of World Preclinical Congress, taking place June 18-21, 2018 in Boston, MA. For more details, please visit: http://www.worldpreclinicalcongress.com
Dr. Andrew Bradbury talks about his latest work using NGS to build a single donor library, and shares lessons he has learned along the way. He describes the unique approach they are using at Specifica and outlines tips for creating antibody libraries with improved diversity and developability. For more information, please visit http://www.PEGSummit.com/Phage-Display/
Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics. For more information, please visit http://www.MolecularDXEurope.com/MDXE_Content.aspx?id=190671
Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward. For more information please visit http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/
Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Technologies for Cell-Free DNA Analysis conference, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal. For more information, please visit http://www.MolecularDXEurope.com/Cell-Free-DNA-Technology/
As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for: · Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health · Developing novel endpoints based on an individual’s day-to-day experience · Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points · Optimizing study recruitment and protocol compliance through digital channels For more information, please visit http://www.Bio-ITWorld.com
Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for April 30 - May 4, 2018 in Boston, with the antibodies program set for May 2-3. For more information, please visit http://www.PEGSummit.com/Engineering-Antibodies
Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is speaking at the Advances in prenatal Molecular Diagnostics meeting, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal For more information, please visit http://www.MolecularDXEurope.com/Prenatal-Dx/
Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change. For more information, please visit http://www.MolecularDXEurope.com/mdxe_content.aspx?id=190671
Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays for Biologics at the PEGS Summit this May 3-4 in Boston, MA! For more information, please visit http://www.PEGSummit.com/Bioassays-Conference/
Dr. William Hallett outlines what he considers some of the greatest obstacles to assess immunogenicity of biologics. He also comments on the reason behind the new requirement for lower cut-point in assays, how to accelerate Biobetters to the market in the world of Biosimilars, and advice for the industry in biologic development to accelerate FDA approval. For more information, please visit http://www.PEGSummit.com/Immunogenicity/
An interview with the 2018 Young Scientist Keynote, Dr. Kipp Weiskopf. Insights into new exciting developments in the growing field of cancer immunotherapy, perspectives on where this field is heading, and trends shaping the next generation of cancer immunotherapy. For more details, please visit: http://www.PEGSummit.com/Plenary-Keynote/
Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them. Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: http://www.SCOPESummit.com
Dr. Wells, Professor of Pharmaceutical Chemistry at the University of California, San Francisco, shares insights about his upcoming and the keynote presentation in the Emerging Technologies for Antibody Discovery conference being held on January 11th and 12th at PepTalk. For more information, please visit http://www.CHI-PepTalk.com/Antibody-Discovery/
In this podcast from CHI on September 20, 2017, Stephen Carey speaks about Omniox’s quest to deliver oxygen into the tumor microenvironment to improve immunotherapy response. He also remarks on the challenges facing tumor microenvironment research and strategies to overcome them. To see him in person, check out the Targeting the Tumor Microenvironment conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Tumor-Microenvironment/
Real World Evidence (RWE) is today’s big data challenge in Life Sciences. Medical records, registries, consultation reports, insurance claims, pharmacy data, social media, and patient surveys all contain valuable insights that Life Sciences organizations need to ascertain and prove the safety, efficacy and value of their drugs and medical devices. Join us to learn from our expert panelists as they discuss how Pharmaceutical and Medical Device Manufacturers are accelerating the development of RWE with a metadata-driven, semantically-enriched approach that enables them to: • Unify, harmonize and ensure governance of information from diverse data sources • Transform data into evidence that proves product efficacy and safety • Identify data patterns, connections, and relationships for faster time to insight For more information please visit http://www.Bio-ITWorld.com
In this podcast from CHI on September, Vancheswaran Gopalakrishnan and Jennifer Wargo speak about their work at the MD Anderson Cancer Center to understand the role of the microbiome in melanoma therapies, and the challenges that microbiome researchers are facing as this emerging field continues to move forward. To see him in person, check out the Microboime in Cancer Immunotherapy conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Microbiome-Immunotherapy/
Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current research. Dr. Vora is speaking at the Advances in Prenatal Molecular Diagnostics conference, taking place November 28-29, 2017 in Cambridge, MA. For details, visit: http://www.Healthtech.com/Prenatal-Diagnostics/
This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people introducing new ADC products in the clinical setting; and some of the most exciting new developments and emerging applications for ADCs. He shares his thoughts on ADCs that target both cancer initiating cells and differentiated cancer cells and clinical results; escape mechanisms tumor cells use to avoid destruction by ADCs; how perception shifted over the last three –four years on ADCs; and how can ADCs be combined with immuno-oncology approaches.
Tauseef Butt, CEO of Progenra Inc. speaks to CHI on September 8, 2017. Dr. Butt will be presenting during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include the benefits and challenges of immunomodulatory small molecules, Ubiquitin Protease (USP7) Inhibitors performance in animal models, Progenra’s discovery platform and their plans for developing other immunomodulatory strategies.
Dan Peer of Tel Aviv University speaks to CHI on September 8, 2017. Prof. Peer will be speaking during Emerging Oligonucleotide Therapeutics, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include how to deliver RNA molecules into specific target tissues, especially leukocytes, via systemic administration, working with RNA, CRISPR-based gene editing and clinical applications for Lipid-Based Nanoparticles and Extracellular Vesicles.
© 2020-2025 Ivy Podcast Discovery LLC
